Return to study ST000138 main page
MB Sample ID: SA007513
Local Sample ID: | PE0332 |
Subject ID: | SU000157 |
Subject Type: | Human |
Subject Species: | Homo sapiens |
Taxonomy ID: | 9606 |
Human Inclusion Criteria: | Participants with a baseline fasting glucose < 100 mg/dl and a fasting glucose ? 100 mg/dl at the end of atenolol treatment are considered to have developed IFG. Participants with a baseline fasting glucose < 100 mg/dl and a fasting glucose that remained < 100 mg/dl at the end of atenolol treatment are considered to have not developed IFG. |
Human Exclusion Criteria: | Participants with a fasting glucose ? 100 mg/dl at baseline are excluded from this study. |
Species Group: | Human |
Select appropriate tab below to view additional metadata details:
Collection:
Collection ID: | CO000141 |
Collection Summary: | At baseline and after completion of atenolol treatment, blood samples were collected and spun. Serum and plasma fractions were stored at -80C. 200 uL of plasma were aliquoted for metabolomics analyses. Sample Type: Blood serum Volume Collected: 200 uL |
Sample Type: | Blood |